Shanghai Rochi Pharmaceutical Technology Co., Ltd. is located in Shanghai Zhangjiang Hi-Tech Biological and Pharmaceutical Innovation Base. It is a comprehensive service enterprise integrating innovative drugs, improved new drugs, generic APIs & intermediates, and preparation research and development, production and sales. The company's products mainly involve therapeutic fields such as cardiovascular, central nervous system, hypoglycemic, antiviral and anticancer. Through the CXMO business model, the company provides customers with one-stop project development services, from laboratory research and development, process optimization to commercial production, and can provide products from milligrams to tonnages.
Company set up the year
Number of global customers
Number of R&D innovation projects
Number of products owned
WE ARE PROFESSIONAL
Here is a brief introduction of product classification, patiently communicate and serve customers, achieve customer goals, think what customers think, exceed customer expectations, and fully meet customers' requirements for quality, documents, time, cost, system, and intellectual property protection and so on. Build a long-term and stable partnership with a community of shared future to achieve a win-win situation.
Services & Solutions
Rochi Pharma can provide one-stop CMC services from drug discovery, pre-formulation research, drug analysis, stability research, drug product development, etc.
Rochi Pharma provides comprehensive CRDMO (Contract Research, Development and Manufacturing Organization) services from drug discovery to commercial manufacturing. Our vertically integrated peptide platform covers from natural amino acid, unnatural amino acid, conjugate, API to drug product, coupled with comprehensive analytical support and CMC writing service, supporting our customers bring their peptide therapeutics to market faster.
Rochi Pharma has comprehensive research, development capabilities and equipment including medicinal chemistry, synthetic chemistry, process research and analytical support. Through our excellent and experienced team of chemists, with professional synthesis technology and familiar various reaction types, we can provide customers with high-quality and high-efficiency chemical synthesis research services, and can synthesize small quantities of compounds. The method is translated into a multi-kilogram process route, and ultimately commercialized by optimizing the process and cost, ensuring that the research and commercialization of the project is completed within very strict time constraints.
Rochi Pharma has established a relevant cell bank, which can provide customers with a full range of cell and gene therapy CRDMO services such as cells, cell therapy, and viral AAV.
We provide a comprehensive range of services in clinical development. We provide Phase I to Phase IV clinical development services & BE (Bioequivalence), for products including pharmaceuticals, biologics, and medical devices. With expertise spanning all major therapeutic areas, we deliver the unique blend of an experienced team, combined with the creativity, responsiveness, and customer centric-focus of a highly nimble organization. This forward-thinking approach has allowed us to work on a variety of projects ranging from first-in-human products to marketed drugs and devices.
Rochi Pharma’s commitment in biocatalysis has not only been reputed by customers around the world, but also strongly supported by government environmental protection departments.
We continue to pursue excellence, go beyond ourselves, step by step, through the selection of high-quality talents, to achieve the solid development of individuals and companies
Generics R&D and manufacturing
Provides CRDMO services for new drug development from discovery to commercial, meeting any material requirement at any scale and covering all categories for all synthetic molecular modalities, including small molecules, oligonucleotides, peptides and complex conjugates
Has abundant of experience in molecular biology, cell biology, in vitro biology, institutional biology and other biological fields, and cooperates with a variety of biotechnology and professional scientific research teams.
Clinical trial service platform
Providing a comprehensive range of services in clinical development. We provide Phase I to Phase IV clinical research development services and Bioequivalence (BE) studies for products including pharmaceuticals, biologics, and medical devices
Cell and Gene Therapies
A Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs around the world.
We continue to explore and apply a variety of new chemical, biological and engineering technologies to achieve more efficient, safer, greener process development and production, and provide customers with new process solutions from research and development (CRO) to commercial production (CDMO&CMO).
Many customers are asking what is the process of importing raw materials? How long does the lead time take? And what kind of qualifications do you need?
Functional dyspepsia (FD) is a common functional gastrointestinal disease, which is a group of persistent or recurrent epigastric pain, epigastric burning sensation, postprandial fullness discomfort, early satiety, excessive belching, epigastric distension Gastrointestinal symptoms, such as gas and nausea, are the main manifestations, which can appear together with symptoms of gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS). Some of the onset and recurrence are related to mental and psychological factors and diet.
On November 13, my country's newly released "Clinical Practice Guidelines for Hypertension in China" (hereinafter referred to as "Guidelines") lowered the diagnostic criteria for hypertension: the original diagnostic criteria for hypertension was 140/90mmHg, and the revised one was ≥130/90mmHg. 80mmHg. In other words, the "healthy" people whose blood pressure was between 130/80 mmHg and 140/90 mmHg will completely become hypertensive patients today. Perhaps, there are not a few friends who have been "successful". A study published in 2019 showed that there are as many as 243 million people in this group in China. In the field of hypertension treatment, blockbuster drugs have always been released frequently. So, what impact will the lowering of the diagnostic criteria have on the market?